Morpho-functional analysis of patient-derived xenografts reveals differential impact of gastric cancer and chemotherapy on the tumor ecosystem, affecting immune check point, metabolism, and sarcopenia
Objectives Gastric cancer (GC) is an aggressive disease due to late diagnosis resulting from the lack of easy diagnostic tools, resistances toward immunotherapy (due to low PD-L1 expression), or chemotherapies (due to p53 mutations), and comorbidity factors, notably muscle atrophy. To improve our understanding of this complex pathology, we established patient-derived xenograft (PDX) models and characterized the tumor ecosystem using a morpho-functional approach combining high-resolution imaging with molecular analyses, regarding the expression of relevant therapeutic biomarkers and the presence of muscle atrophy. Materials and methods GC tissues samples were implanted in nude mice. Established PDX, treated with cisplatin or not, were imaged by magnetic resonance imaging (MRI) and analyzed for the expression of relevant biomarkers (p53, PD-L1, PD-1, HER-2, CDX2, CAIX, CD31, a-SAM) and by transcriptomics. Results Three well-differentiated, one moderately and one poorly differentiated adenocarcinomas were established. All retained the architectural and histological features of their primary tumors. MRI allowed in-real-time evaluation of differences between PDX, in terms of substructure, post-therapeutic changes, and muscle atrophy. Immunohistochemistry showed differential expression of p53, HER-2, CDX2, a-SAM, PD-L1, PD-1, CAIX, and CD31 between models and upon cisplatin treatment. Transcriptomics revealed treatment-induced hypoxia and metabolic reprograming in the tumor microenvironment. Conclusion Our PDX models are representative for the heterogeneity and complexity of human tumors, with differences in structure, histology, muscle atrophy, and the different biomarkers making them valuable for the analyses of the impact of platinum drugs or new therapies on the tumor and its microenvironment..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Gastric Cancer - 26(2022), 2 vom: 19. Dez., Seite 220-233 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Venkatasamy, A. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Cisplatin |
|---|
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1007/s10120-022-01359-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR04944610X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR04944610X | ||
| 003 | DE-627 | ||
| 005 | 20230510063925.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10120-022-01359-w |2 doi | |
| 035 | |a (DE-627)SPR04944610X | ||
| 035 | |a (SPR)s10120-022-01359-w-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Venkatasamy, A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Morpho-functional analysis of patient-derived xenografts reveals differential impact of gastric cancer and chemotherapy on the tumor ecosystem, affecting immune check point, metabolism, and sarcopenia |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Objectives Gastric cancer (GC) is an aggressive disease due to late diagnosis resulting from the lack of easy diagnostic tools, resistances toward immunotherapy (due to low PD-L1 expression), or chemotherapies (due to p53 mutations), and comorbidity factors, notably muscle atrophy. To improve our understanding of this complex pathology, we established patient-derived xenograft (PDX) models and characterized the tumor ecosystem using a morpho-functional approach combining high-resolution imaging with molecular analyses, regarding the expression of relevant therapeutic biomarkers and the presence of muscle atrophy. Materials and methods GC tissues samples were implanted in nude mice. Established PDX, treated with cisplatin or not, were imaged by magnetic resonance imaging (MRI) and analyzed for the expression of relevant biomarkers (p53, PD-L1, PD-1, HER-2, CDX2, CAIX, CD31, a-SAM) and by transcriptomics. Results Three well-differentiated, one moderately and one poorly differentiated adenocarcinomas were established. All retained the architectural and histological features of their primary tumors. MRI allowed in-real-time evaluation of differences between PDX, in terms of substructure, post-therapeutic changes, and muscle atrophy. Immunohistochemistry showed differential expression of p53, HER-2, CDX2, a-SAM, PD-L1, PD-1, CAIX, and CD31 between models and upon cisplatin treatment. Transcriptomics revealed treatment-induced hypoxia and metabolic reprograming in the tumor microenvironment. Conclusion Our PDX models are representative for the heterogeneity and complexity of human tumors, with differences in structure, histology, muscle atrophy, and the different biomarkers making them valuable for the analyses of the impact of platinum drugs or new therapies on the tumor and its microenvironment. | ||
| 650 | 4 | |a Gastric cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cisplatin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Magnetic resonance imaging |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mouse models |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a PD-L1 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immune checkpoint signaling hypoxia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a p53 |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Guerin, E. |4 aut | |
| 700 | 1 | |a Reichardt, W. |4 aut | |
| 700 | 1 | |a Devignot, V. |4 aut | |
| 700 | 1 | |a Chenard, M. P. |4 aut | |
| 700 | 1 | |a Miguet, L. |4 aut | |
| 700 | 1 | |a Romain, B. |4 aut | |
| 700 | 1 | |a Jung, A. C. |4 aut | |
| 700 | 1 | |a Gross, I. |4 aut | |
| 700 | 1 | |a Gaiddon, C. |4 aut | |
| 700 | 1 | |a Mellitzer, G. |0 (orcid)0000-0003-4467-0789 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastric Cancer |d Springer-Verlag, 2002 |g 26(2022), 2 vom: 19. Dez., Seite 220-233 |w (DE-627)SPR009286586 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2022 |g number:2 |g day:19 |g month:12 |g pages:220-233 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10120-022-01359-w |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2022 |e 2 |b 19 |c 12 |h 220-233 | ||